A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Not Applicable

Not yet recruiting

• Conditions: Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
• Interventions: Biological: BS01; Other: Sham procedure control

• Registration Number: NCT07158775
• Lead Sponsor: Bionic Sight LLC

Brief Summary

This is a Phase 1/2 study, multi-center, dose-escalation interventional study of BS01 in subjects with GA secondary to dry AMD. Part 1 is an open label dose-escalation study; Part 2 is a dose-expansion study with dose(s) selected from Part 1 based on a benefit/risk assessment, and an untreated (sham injection) group to allow for a controlled comparison of efficacy and safety.

This is a seamless Phase 1/2 study in up to 10 patients for Phase 1 and 30 patients Phase 2 in patients with GA secondary to dry AMD.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-09
• Study First Submitted: 2025-09-04
• Study First Submitted QC: 2025-09-04
• Last Update Submitted: 2025-09-04
• Study First Posted: 2025-09-08
• Last Update Posted: 2025-09-08
• Study Start: 2025-11-01
• Primary Completion: 2027-12
• Study Completion: 2031-12-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

General Inclusion Criteria

1. Signed informed consent obtained before screening.
2. Men or women between 50 and 85 years of age inclusive at the time of signing the informed consent.

Ophthalmic Inclusion Criteria

1. Geographic atrophy with some macula foveal involvement secondary to dry AMD.
2. Total GA area ≥ 5 and ≤ 17.5 mm2 (2 and 7 disk areas respectively), based on Heidelberg Region Finder or equivalent automated software.
3. If GA is multifocal, at least one focal lesion should measure ≥ 1.25 mm2 (0.5 disk area) to ensure measurable focal effects for efficacy evaluation.
4. Composite lesion encompassing confluent GA regions with total area meeting thresholds given in 2 above.
5. GA in part within 1200 microns from the foveal center.
6. The atrophic lesion must be able to be photographed in its entirety.
7. BCVA between 20/50 to 20/400, inclusive, using letter score per EDTRS chart.
8. Clear ocular media and adequate pupillary dilatation in both eyes to allow for all imaging procedures, including good quality stereoscopic fundus photography and fundus autofluorescence (FAF).
9. Central fixation.

Exclusion Criteria

General Exclusion Criteria

1. Previous therapeutic radiation in the region of the SE.
2. Previous treatment with any ocular or systemic gene transfer product.
3. Any treatment with an investigational agent in the past 60 days for any condition.
4. Women who are pregnant or nursing.
5. Known hypersensitivity to topical ocular anesthetics or diagnostic drops to be used during the study.
6. Any other medical condition, which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromises patient safety, or interferes with the interpretation of the study results.

Ophthalmic Exclusion Criteria

1. > 30% difference of BCVA using EDTRS in two baseline visual acuity assessments with at least 14 days apart during screening.
2. Any intraocular surgery or thermal laser within 3 months of study entry. Any prior thermal laser in the macular region, regardless of indication.
3. Any ocular or periocular infection (including blepharitis), or ocular surface inflammation in the past 12 weeks.
4. History of any of the following procedures: Posterior vitrectomy, filtering surgery (e.g., trabeculectomy), glaucoma drainage device, corneal transplant, or retinal detachment.
5. Any sign of diabetic retinopathy in either eye.
6. Intraocular pressure (IOP) > 25 mmHg in either eye.
7. Completely atrophic centrally located lesions based on ellipsoid zone (EZ) loss in spectraldomain optical coherence tomography (SD-OCT).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BS01 (low dose)	BS01	-
Sham control	Sham procedure control	-
BS01 (high dose)	BS01	-

Primary Outcome Measures

Name	Time	Method
[Phase 1] Number of the dose limiting toxicities (DLTs), incident and severity of ocular and non-ocular Study Drug-related adverse events (SDAE), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	12 months
[Phase 2] Change from baseline in BCVA (Best Corrected Visual Acuity)	12 months